Key Players
Competitive Landscape
Drug makers and fabs approve a DMSO source only after audits, impurity profiles and trial lots, and a qualified grade then stays in place for years. gChem holds a unique position as the single Western Hemisphere producer, with 100% domestic sourcing of raw materials.[4] Arkema serves battery and electronics customers from a broader specialty chemicals base.[10]
Hubei Xingfa, Shandong Haike and Jiangsu Jiuyi compete on price for industrial grade, and distributors such as IRO Group and Charkit Chemical move volume to formulators. Toray Fine Chemicals and Tokyo Chemical Industry compete on purity for drug and laboratory users.
Company developments mapped to drivers, trends and opportunities (2026-2036)
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| July 2026: Repligen agrees to buy BioLife Solutions. | Cell therapy commercialisation. | Consolidation of freezing media suppliers. | Pharmaceutical-grade supply contracts. |
| October 2026: GlobalFoundries chosen for two Malta fabs. | US chip capacity build-out. | Domestic sourcing of fab chemicals. | Electronic-grade qualification. |
| April 2026: FM review of the gChem plant. | Single-site supply risk. | Buyer focus on resilience. | Second-source and safety stock deals. |
Source: Future Market Insights, Dimethyl Sulfoxide (DMSO) Market Report, 2026-2036.
Buyers are asking for a second qualified source after supply scares, and producers able to offer two plants or a large safety stock will gain the longest contracts.
Who leads the dimethyl sulfoxide (DMSO) market?
gChem leads documented supply in North America, producing millions of pounds a year at one Alabama plant.[4] Arkema follows among the profiled producers with dated 2026 results.[10]
Which companies have documented positions?
gChem documents plant risk engineering and grades.[4] Arkema documents quarterly growth pockets in batteries and electronics.[10] BioLife Solutions documents cell therapy media use as a leading buyer of cryoprotectant.[8]
What should buyers evaluate before approving a supplier?
Purity, water content, metal traces, residual sulfur compounds and batch consistency are checked against the grade required. Buyers also review regulatory files, plant audits, packaging and the supplier backup plan for outages.
How is competition expected to change through 2036?
Electronic and pharmaceutical grades will carry most margin growth, and producers with purification and dual sites will gain share of those buyers. Industrial grade will stay a price contest among Chinese producers and distributors.
Representative Company Overview
| Company | Positioning | Recent development |
|---|---|---|
| gChem | Only Western Hemisphere DMSO producer, single integrated plant | April 2026: FM review of plant risk engineering. |
| Arkema | Specialty chemicals group with thiochemicals | July 2026: Q2 EBITDA up 7.4% to EUR 391 million. |
| Toray Fine Chemicals | Japanese DMSO producer within the Toray group | 2026: pharmaceutical and electronic grade supply to Japanese users. |
Research Methodology
The companies included in the report represent current market structure and do not indicate a market-share ranking. Producer, fab, cell therapy and API facts here come from company releases, SEC filings, industry associations, government notes and trade press published from May 2025 onward.
